Reimagining drugs for a rare brain disorder
A team of researchers has developed a new method to screen FDA-approved drugs to determine if they could be repurposed or improved to help patients with a rare, debilitating disease of the nervous system.
See also stories tagged with Drug discovery
A team of researchers has developed a new method to screen FDA-approved drugs to determine if they could be repurposed or improved to help patients with a rare, debilitating disease of the nervous system.
An advanced imaging-based method from scientists at Scripps Research offers a new way of studying mitochondria.
A lethal microbial pathogen is lurking in warm freshwater ponds, reservoirs, and rivers around the globe: Naegleria fowleri, colloquially called brain-eating amoeba, which causes the disease primary amebic meningoencephalitis ...
Researchers from the University of Sussex and Universal Quantum have demonstrated for the first time that quantum bits (qubits) can directly transfer between quantum computer microchips and demonstrated this with record-breaking ...
In the cell, messenger RNAs—or mRNAs—are translated into proteins and eventually degraded, but the relationship between translation and mRNA decay remains cloudy. FMI researchers developed an innovative tool to control ...
Pharmaceutical synthesis is often quite complex; simplifications are needed to speed up the initial phase of drug development and lower the cost of generic production. Now, in a study recently published in Science, researchers ...
The laboratories of Brian Bachmann, professor of chemistry, biochemistry and pharmacology, and Jonathan Irish, associate professor of cell and developmental biology and pathology, microbiology and immunology, have developed ...
Developing new antifungal treatments is a rising health priority due to an alarming rise in multidrug-resistant fungal "superbugs" that evade medications clinicians have relied on for decades.
The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chinese researchers.
New research uses AlphaFold, an artificial intelligence (AI)-powered protein structure database, to accelerate the design and synthesis of a drug to treat hepatocellular carcinoma (HCC), the most common type of primary liver ...